Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Blood (2017) 130 (Supplement 1): 3146.

https://doi.org/10.1182/blood.V130.Suppl_1.3146.3146

Published: 2017

Journal Articles

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Blood (2016) 127 (9): 1109–1116.

https://doi.org/10.1182/blood-2015-11-679415

Published: 2016

Includes: Supplemental data

Journal Articles

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Johan Lund, MD, Sigrid Karstorp, MD, Evren Alici, MD PhD, Astrid Gruber, MD PhD, Birgitta Lauri, MD, Cecilie Blimark, MD PhD, Agneta Swedin, MD PhD, Markus Hansson, MD PhD, Karin Forsberg, MD, Lucia Ahlberg, MD, Carlsson Conny, MD, Anders Waage, MD PhD, Peter Gimsing, Annette Juul Vangsted, MD PhD, Ulf Christian Frølund, MD, Mats Hardling, Ulf-Henrik Mellqvist, MD PhD, Hareth Nahi

Blood (2015) 126 (23): 3047.

https://doi.org/10.1182/blood.V126.23.3047.3047

Published: 2015

Journal Articles

Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach

Johan Lund, MD, Evren Alici, MD PhD, Michael Chrobok, MD, Astrid Gruber, MD PhD, Tahamtan Ahmadi, Imran Khan, Hareth Nahi

Blood (2015) 126 (23): 5366.

https://doi.org/10.1182/blood.V126.23.5366.5366

Published: 2015

Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD

Blood (2015) 126 (23): 26.

https://doi.org/10.1182/blood.V126.23.26.26

Published: 2015

Journal Articles

Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG)

Blood (2014) 124 (21): 179.

https://doi.org/10.1182/blood.V124.21.179.179

Published: 2014

Journal Articles

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study

Blood (2013) 121 (25): 5055–5063.

https://doi.org/10.1182/blood-2012-11-469452

Published: 2013

Journal Articles

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

Blood (2013) 121 (23): 4647–4654.

https://doi.org/10.1182/blood-2012-11-464503

Published: 2013

Journal Articles

Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.

Hareth Nahi, Johan Liwing, Anders Aldrin, Johan Andreasson, Cecilie Blimark, MD, Kristina Carlson, Jon Enestig, Max Flogegård, Karin Forsberg, Astrid Gruber, MD, PhD, Peter Johansson, MD, PhD, Helene Kviele, Birgitta Lauri, Ulf-Henrik Mellqvist, MD, PhD, Per Näsman, Agneta Swedin, Magnus Svensson, Katarina Uttervall, MD, PhD-student, Johan Aschan, MD, PhD

Blood (2012) 120 (21): 2970.

https://doi.org/10.1182/blood.V120.21.2970.2970

Published: 2012

Journal Articles

Follow-up of Real Life Treated Multiple Myeloma Patients: Response, Disease Progression and Overall Survival,

Hareth Nahi, Johan Liwing, Katarina Uttervall, Johan Andreasson, Astrid Gruber, MD, PhD, Per Näsman, Johan Aschan

Blood (2011) 118 (21): 3937.

https://doi.org/10.1182/blood.V118.21.3937.3937

Published: 2011

Journal Articles

Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.

Gosta Gahrton, MD, PhD, Bo Bjorkstrand, MD, PhD, Simona Iacobelli, Statistician, Ute Hegenbart, MD, Astrid Gruber, MD, PhD, Hildegard Greinix, MD, Liisa Volin, MD, Franco Narni, MD, Pellegrino Musto, MD, Meral Beksac, MD, Alberto Bosi, MD, Giuseppe Milone, MD, Paolo Corradini, MD, Hartmut Goldschmidt, MD, Theo de Witte, MD, Curly Morris, MD, Dietger Niederwieser, MD

Blood (2009) 114 (22): 52.

https://doi.org/10.1182/blood.V114.22.52.52

Published: 2009

Journal Articles

Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.

Blood (2009) 114 (22): 530.

https://doi.org/10.1182/blood.V114.22.530.530

Published: 2009

Journal Articles

Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma

Masih Ostad, Margareta Andersson, Astrid Gruber, Anne Sundblad

Blood (2008) 111 (5): 2725–2732.

https://doi.org/10.1182/blood-2006-11-056242

Published: 2008

Includes: Supplemental data

Journal Articles

Interferon α down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells

Dawei Xu, Sven Erickson, Michael Szeps, Astrid Gruber, Olle Sangfelt, Stefan Einhorn, Pavel Pisa, Dan Grandér

Blood (2000) 96 (13): 4313–4318.

https://doi.org/10.1182/blood.V96.13.4313

Published: 2000

NARROW

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.

Follow-up of Real Life Treated Multiple Myeloma Patients: Response, Disease Progression and Overall Survival,

Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.

Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.

Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma

Interferon α down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only